Word

ETHERNA

Status

Pending

Status Code

730

Status Date

Tuesday, August 13, 2024

Serial Number

97728325

Mark Type

4

Filing Date

Thursday, December 22, 2022

Published for Opposition

Tuesday, January 2, 2024

Trademark Owner History

eTheRNA immunotherapies NV - Owner At Publication

Classifications

40 Custom manufacture of pharmaceutical and medical preparations; custom manufacture of mRNA molecules; custom manufacture of mRNA molecules formulated in lipid nanoparticles; custom manufacture of mRNA for use in vaccines, cell therapy, gene editing, protein replacement, and antibodies; provision of information, advice and consultancy services relating to all of the aforesaid

5 Vaccines; vaccine adjuvants; medical, biological, and pharmaceutical preparations for medical use, namely, preparations containing messenger RNA for preventing and treating viruses, medical disorders, and diseases, namely, viral infections, bacterial infections, cancer, viral, bacterial, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders; mRNA-based therapeutics and therapeutic agents for in prevention and treatment of viruses, medical disorders, and diseases, namely, viral infections, bacterial infections, cancer, viral, bacterial, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders; lipid nanoparticles for pharmaceutical, medical or diagnostic purposes for preventing and treating viruses, medical disorders, and diseases, namely, viral infections, bacterial infections, cancer, viral, bacterial, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders; drug carriers for medical use, namely, drug delivery agents consisting of lipid nanoparticles that facilitate delivery of a wide range of pharmaceuticals; lipid nanoparticles for drug delivery sold as an integral component of drugs in the nature of pharmaceutical preparations for preventing and treating viruses, medical disorders, and diseases, viral infections, bacterial infections, cancer, viral, bacterial, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders; pharmaceutical preparations, namely, messenger RNA and delivery agents comprised of lipid nanoparticle carriers and polymers for the delivery of mRNA to human cells for preventing and treating viruses, medical disorders, and diseases, namely, viral infections, bacterial infections, cancer, viral, bacterial, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders

1 Biological preparations for scientific and research purposes for boosting cells in the immune system for improved therapies; biological preparations for scientific and research purposes, namely, a mRNA-based composition for enhancing immunities; biological preparations in the nature of genetically modified cells and vectors for scientific and research purposes; biological and chemical reagents including complexes of these molecules for research purposes, for clinical research, clinical chemistry, clinical trials, scientific research, medical research, laboratory research, and for industrial use, namely, for use in the manufacture of pharmaceuticals

42 Scientific research and development; pharmaceutical research and development services; medical research and development services; scientific, pharmaceutical, and medical research and development in the field of mRNA therapeutics; scientific, pharmaceutical, and medical research and development in the field of proprietary lipids and lipid nanoparticle formulations for the delivery of mRNA therapeutics for the treatment of various medical disorders, cancer, and infectious diseases

Trademark Events

Dec 26, 2022

New Application Entered

Jan 19, 2023

New Application Office Supplied Data Entered

Sep 22, 2023

Assigned To Examiner

Oct 6, 2023

Non-Final Action Written

Oct 6, 2023

Non-Final Action E-Mailed

Oct 6, 2023

Notification Of Non-Final Action E-Mailed

Oct 26, 2023

Teas Response To Office Action Received

Oct 26, 2023

Correspondence Received In Law Office

Oct 26, 2023

Teas/Email Correspondence Entered

Nov 28, 2023

Approved For Pub - Principal Register

Dec 13, 2023

Notification Of Notice Of Publication E-Mailed

Jan 2, 2024

Published For Opposition

Jan 2, 2024

Official Gazette Publication Confirmation E-Mailed

Feb 27, 2024

Noa E-Mailed - Sou Required From Applicant

Aug 13, 2024

Sou Teas Extension Received

Aug 13, 2024

Notice Of Approval Of Extension Request E-Mailed

Aug 13, 2024

Sou Extension 1 Filed

Aug 13, 2024

Sou Extension 1 Granted

Aug 16, 2024

Teas Statement Of Use Received